Cold agglutinin disease by NovelMed Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

Cold agglutinin diseaseis under clinical development by NovelMed Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

Related Posts

STAT+: Pharmalittle: We’re reading about a CEO change a...

Feb 21, 2024

Vaccine experts urge more inclusivity in clinical trials

Sep 6, 2023

Risk adjusted net present value: What is the current va...

Mar 13, 2024